Clinical hurdles for curcumin and piperine nanoparticles in prostate cancer treatment. a bridge too far or a path to clinical reality?
Loading...
Authors
Author (Corporation)
Publication date
2026
Type of student thesis
Course of study
Collections
Type
01A - Journal article
Editors
Editor (Corporation)
Supervisor
Parent work
Expert Opinion on Drug Delivery
Special issue
DOI of the original publication
Link
Series
Series number
Volume
Issue / Number
Pages / Duration
Patent number
Publisher / Publishing institution
Taylor & Francis
Place of publication / Event location
Edition
Version
Programming language
Assignee
Practice partner / Client
Abstract
While nano-encapsulation enhances the therapeutic index of curcumin, clinical translation remains stalled by a reliance on passive targeting and insufficient manufacturing scalability. Future success depends on shifting from 'beaker' synthesis to microfluidic production (Quality by Design) and adopting active targeting (e.g. PSMA-directed delivery) to penetrate the prostate stroma. Without these strategic pivots and biomarker-driven trials, CPNs risk remaining an academic curiosity rather than evolving into a viable clinical intervention.
Keywords
Subject (DDC)
Event
Exhibition start date
Exhibition end date
Conference start date
Conference end date
Date of the last check
ISBN
ISSN
1742-5247
1744-7593
1744-7593
Language
English
Created during FHNW affiliation
Yes
Strategic action fields FHNW
Publication status
Published
Review
Peer review of the complete publication
Open access category
Hybrid
License
Citation
Yakubu, J., Tagit, O., & Pandey, A. V. (2026). Clinical hurdles for curcumin and piperine nanoparticles in prostate cancer treatment. a bridge too far or a path to clinical reality? Expert Opinion on Drug Delivery. https://doi.org/10.1080/17425247.2026.2619094